EP Patent
EP3567042A1 — Cdk inhibitors
Assigned to G1 Therapeutics Inc · Expires 2019-11-13 · 7y expired
What this patent protects
Compounds of formula I, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
USPTO Abstract
Compounds of formula I, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.